Table 1.
Patient characteristics
| Characteristics | N = 20 |
|---|---|
| Age | |
| Median years (range) | 70 years (55–77 years) |
| Gender | |
| Male | 12 |
| Female | 8 |
| ECOG PS | |
| 0 | 9 |
| 1 | 9 |
| 2 | 2 |
| Smoking history | |
| Yes | 12 |
| No | 8 |
| Histology | |
| ADC | 16 |
| SCC | 3 |
| Other | 1 |
| Clinical staging | |
| III | 3 |
| IV | 12 |
| Recurrence after surgery | 5 |
| EGFR mutation status | |
| Wild type | 17 |
| Mutant type | 3 |
| Number of treatment lines of prior nivolumab | |
| 1 | 13 |
| 2 | 3 |
| 3 | 1 |
| Number of treatment lines between nivolumab and docetaxel plus ramucirumab | |
| 0 | 17 |
| 1 | 3 |
| Duration of nivolumab treatment | |
| Median days (range) | 68 days (29–554) |
| Median number of docetaxel plus ramucirumab cycles (range) | 4 cycles (1–11) |
| †Prophylactic administration of G‐CSF† | |
| Yes | 18 |
| No | 2 |
†
Granulocyte‐colony stimulating factor (G‐CSF) was administered within 72 hours of docetaxel plus ramucirumab. ADC, adenocarcinoma; ECOG, Eastern Cooperative Oncology Group; G‐CSF, granulocyte‐colony stimulating factor; PS, performance status; SCC, squamous cell carcinoma.